GoAI
Get started
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc.

UNCY

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$5.36

−$0.27 · -4.80%

Aug 24, 10:33 AM ET

UNCY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

31

Expensive

Momentum

27

Weakening

Sentiment

54

Mixed

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Shalabh K. Gupta
Listed since
Jul 12, 2021
Employees
21

Market position

Day range

Current $5.36

52-week range

Current $5.36

Open
$5.64
Previous close
$5.63
Volume
204.18K
0.16× average
Average volume
1.24M
Average daily volume
Market cap
143.11M USD
Beta
1.78
Market reference 1
50-day average
$5.8109
-7.76% below average
200-day average
$6.4037
-16.30% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
62.67M USD
P/E (TTM)
-3.2×
P/B (TTM)
2.71×
P/S (TTM)
0×
EV / EBITDA
-2.42×
Earnings yield
-28.97%
Free cash flow yield
-34.19%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-87.94%
Return on assets
-54.04%
Return on invested capital
-97.11%

Financial health

Debt / equity
0.01×
Current ratio
2.59×
Altman Z-score
1.31
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends563%-1288%-3138%-4988%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Operating margin, FY2022: -1898.21%Operating margin, FY2023: -3077.63%Net margin, FY2022: -1898.84%Net margin, FY2023: -4525.04%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Operating margin FY2022 -1898.21%. Operating margin FY2023 -3077.63%. Net margin FY2022 -1898.84%. Net margin FY2023 -4525.04%.

Income trends

Revenue

675K USD-29.02%

Operating income

−29.52M USD+8.10%

Net income

−26.56M USD+27.70%
Income trends across reported periods4.72M USD−10.35M USD−25.43M USD−40.5M USDRevenue, FY2022: 951K USDRevenue, FY2023: 675K USDOperating income, FY2021: −8.98M USDOperating income, FY2022: −18.05M USDOperating income, FY2023: −20.77M USDOperating income, FY2024: −32.12M USDOperating income, FY2025: −29.52M USDNet income, FY2021: −10.02M USDNet income, FY2022: −18.06M USDNet income, FY2023: −30.54M USDNet income, FY2024: −36.73M USDNet income, FY2025: −26.56M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 951K USD. Revenue FY2023 675K USD. Operating income FY2021 −8.98M USD. Operating income FY2022 −18.05M USD. Operating income FY2023 −20.77M USD. Operating income FY2024 −32.12M USD. Operating income FY2025 −29.52M USD. Net income FY2021 −10.02M USD. Net income FY2022 −18.06M USD. Net income FY2023 −30.54M USD. Net income FY2024 −36.73M USD. Net income FY2025 −26.56M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue——675K USD951K USD—
Cost of goods sold572K USD————
Gross profit−572K USD—675K USD951K USD—
Research and development9.12M USD20.01M USD12.9M USD12.44M USD6.08M USD
Selling, general, and administrative20.4M USD12.1M USD8.55M USD6.57M USD2.9M USD
Operating expenses28.95M USD32.12M USD21.45M USD19M USD8.98M USD
Interest income1.01M USD1.26M USD615K USD——
Interest expense71K USD71K USD82K USD6K USD628K USD
Depreciation and amortization572K USD428K USD284K USD161K USD13K USD
Operating income−29.52M USD−32.12M USD−20.77M USD−18.05M USD−8.98M USD
Net income−26.56M USD−36.73M USD−30.54M USD−18.06M USD−10.02M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
-295.17%
11 comparable reports
Latest EPS result
-0.06
Estimate -0.47 · Beat by 87.26%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.05-1.03-2-2.98Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -2.76, estimate -0.13, surprise -2023.08%, Miss. Q2 2025, reported May 14, 2025: actual -0.5, estimate -0.667, surprise +25.00%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.52, estimate -0.7, surprise +25.71%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.33, estimate -0.59, surprise +44.07%, Beat. Q1 2026, reported Mar 30, 2026: actual -0.82, estimate -0.46, surprise -78.26%, Miss. Q2 2026, reported May 12, 2026: actual -0.54, estimate -0.55, surprise +1.82%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.06, estimate -0.471, surprise +87.26%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.32, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates23.96M16.12M8.28M439.45KQ4 '24EstimateQ1 '25EstimateQ4 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q4 2024, reported Nov 13, 2024: actual —, estimate 10M USD, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual —, estimate 10M USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual —, estimate 2.37M USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 30, 2026: actual —, estimate 517K USD, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual —, estimate 11.11M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 12, 2026: actual —, estimate 22.22M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 11, 2026: actual —, estimate 902.78K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$22.00

310.45% upside
Past 12 months12-month forecastHigh $22.00Average $22.00Low $22.00

Rating distribution

8 ratings
Strong buy00%
Buy8100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

5 institutions
Noble Capital MarketsmaintainOutperform

UNCY news

globenewswire.com

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor

Read source
globenewswire.com

UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation

BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Block and Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive…

Read source
globenewswire.com

UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation

BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive…

Read source
globenewswire.com

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the…

Read source
businesswire.com

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company's and/or…

Read source
businesswire.com

Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Unicycive Therapeutics, Inc.…

Read source

Corporate actions

Corporate action history

Stock split

Effective Jun 20, 2025

1:10

UNCY peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding UNCY

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
4.04M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.28-0.25%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.4M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.85-0.37%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.2M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$244.14-0.57%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.13M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$383.98-0.87%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
690.16K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.82-0.36%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
467.59K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$197.74-0.20%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
381.87K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$82.87-0.18%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF logoGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC
Market value
146.79K
Weight
0.01%
AUM
1.09B USD
Expense ratio
0.20%
Price / 1D
$91.015-0.33%

Continue in GoAI

Research UNCY

research.disclaimer